![Gregory W. Schafer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gregory W. Schafer
Geen lopende functies
Profiel
Gregory W.
Schafer served as the Chief Financial Officer and Vice President-Finance at Cerus Corp.
from 1997 to 2004.
He was also the Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc. He served as the Chief Financial Officer at Onyx Pharmaceuticals, Inc. from 2006 to 2008.
Schafer was the Chief Financial Officer and Senior Vice President at SillaJen Biotherapeutics, Inc. from 2010 to 2013.
He served as the Chief Operating Officer at Aduro BioTech, Inc. from 2015 to 2018.
Schafer was an Independent Director at Capricor Therapeutics, Inc. from 2013 to 2016.
He worked as a Management Consultant at Deloitte & Touche LLP.
Schafer received his undergraduate degree from the University of Pennsylvania and his MBA from the UCLA Anderson School of Management.
Eerdere bekende functies van Gregory W. Schafer
Bedrijven | Functie | Einde |
---|---|---|
CHINOOK THERAPEUTICS, INC. | Operationeel Directeur | 01-03-2018 |
CAPRICOR THERAPEUTICS, INC. | Directeur/Bestuurslid | 02-06-2016 |
SillaJen Biotherapeutics, Inc.
![]() SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Financieel Directeur/CFO | 01-07-2013 |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Financieel Directeur/CFO | 15-12-2008 |
IntraBiotics Pharmaceuticals, Inc.
![]() IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Financieel Directeur/CFO | 19-08-2005 |
Opleiding van Gregory W. Schafer
University of Pennsylvania | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
CERUS CORPORATION | Health Technology |
CAPRICOR THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
IntraBiotics Pharmaceuticals, Inc.
![]() IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
SillaJen Biotherapeutics, Inc.
![]() SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Aduro BioTech, Inc.
![]() Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Deloitte & Touche LLP
![]() Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |